SEC Comment Letter for TALPHERA, INC. (TLPH) (CIK 0001427925) (TLPH) — Nov 25, 2019

TALPHERA, INC. (TLPH) (CIK 0001427925)
Date: Nov. 25, 2019 · CIK: 0001427925 · Accession: 0000000000-19-015839

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-35068

Date

November 25, 2019

Author

Not clearly detected

Form

UPLOAD

Company

TALPHERA, INC. (TLPH) (CIK 0001427925)

Letter

November 25, 2019 Raffi M. Asadorian Chief Financial Officer ACELRX PHARMACEUTICALS INC 351 Galveston Drive Redwood City, CA 94063 Re:ACELRX PHARMACEUTICALS INC Form 10-K for the Fiscal Year Ended December 31, 2018 Filed March 7, 2019 File No. 001-35068 Dear Mr. Asadorian: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

November 25, 2019
Raffi M. Asadorian
Chief Financial Officer
ACELRX PHARMACEUTICALS INC
351 Galveston Drive
Redwood City, CA 94063
Re:ACELRX PHARMACEUTICALS INC
Form 10-K for the Fiscal Year Ended December 31, 2018
Filed March 7, 2019
File No. 001-35068
Dear Mr. Asadorian:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io